Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database

Junko Abe¹, Ryogo Umetsu², Kanako Mataki³, Yamato Kato⁴, Natsumi Ueda⁴, Yoko Nakayama⁴, Yuuki Hane⁴, Toshinobu Matsui⁴, Haruna Hatahira⁴, Sayaka Sasaoka⁴, Yumi Motooka⁴, Hideaki Hara³, Zenichiro Kato⁵, Yasutomi Kinosada⁶, Naoki Inagaki⁷, Mitsuhiro Nakamura⁴

Affiliations

¹ Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196 Japan ; Medical Database Co., Ltd, 3-11-10 Higashi, Shibuya-ku, Tokyo 150-0011 Japan.
² Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196 Japan ; Clinical Research, Innovation and Education Center, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba Ward, Sendai, Miyagi 980-8574 Japan.
³ Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196 Japan.
⁴ Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196 Japan.
⁵ Department of Pediatrics, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194 Japan ; United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1194 Japan.
⁶ United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1194 Japan.
⁷ Laboratory of Pharmacology, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196 Japan.

PMID: 27330825
PMCID: PMC4915172
DOI: 10.1186/s40780-016-0048-5

Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database

Junko Abe et al. J Pharm Health Care Sci. 2016.

. 2016 Jun 21:2:14.

doi: 10.1186/s40780-016-0048-5. eCollection 2016.

Authors

Affiliations

¹ Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196 Japan ; Medical Database Co., Ltd, 3-11-10 Higashi, Shibuya-ku, Tokyo 150-0011 Japan.
² Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196 Japan ; Clinical Research, Innovation and Education Center, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba Ward, Sendai, Miyagi 980-8574 Japan.
³ Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196 Japan.
⁴ Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196 Japan.
⁵ Department of Pediatrics, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194 Japan ; United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1194 Japan.
⁶ United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1194 Japan.
⁷ Laboratory of Pharmacology, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196 Japan.

PMID: 27330825
PMCID: PMC4915172
DOI: 10.1186/s40780-016-0048-5

Abstract

Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions associated with fatal disorders. Although many causes of SJS/TEN have been proposed, the time-to-onset for SJS/TEN and the relationship between aging and SJS/TEN are still not clear. Therefore, the aim of this study was to determine the relationship between aging and SJS/TEN using the Japanese Adverse Drug Event Report (JADER) database and analyze the time-to-onset profile of SJS/TEN.

Methods: We analyzed reports of SJS/TEN recorded in the JADER database between 2004 and 2015 using an adjusted reporting odds ratio (ROR). We also used Weibull proportional hazards models for each drug to examine the expression patterns of SJS/TEN. We selected the drugs according to the number of the reports associated with SJS/TEN.

Results: The JADER contained 330,686 reports from April 2004 to April 2015. The adjusted RORs for patients in the 0-19-, 20-39-, 60-79-, and ≥ 80-year-old groups from all data extracted from the JADER database were 1.33 (95 % confidence interval [CI], 1.21-1.45), 1.78 (95 % CI, 1.65-1.93), 0.71 (95 % CI, 0.66-0.75), and 0.72 (95 % CI, 0.66-0.79), respectively. The adjusted ROR tended to be higher in patients aged 0-19 years, particularly in patients using antipyretic analgesics, such as loxoprofen or acetaminophen. More than half of the cases of SJS/TEN onset following administration of loxoprofen and acetaminophen occurred within 4 days of the initiation of treatment. The median times-to-onset were 3 days for loxoprofen and 2 days for acetaminophen. The scale parameter α values of loxoprofen and acetaminophen were 9.44 and 6.17, respectively. The upper 95 % CIs of shape parameter β values for the drugs were all less than 1, with the exceptions of those for carbamazepine, ACE inhibitors, and corticosteroids.

Conclusions: Our results suggested that monitoring of younger patients who frequently use antipyretic analgesics is important. These drugs should be used and monitored within the first 2-3 days of treatment in the Japanese population.

Keywords: Japanese Adverse Drug Event Report; Stevens-Johnson syndrome; Toxic epidermal necrolysis.

PubMed Disclaimer

Figures

**Fig. 1**
Histgram for time-to-onset profile of the SJS/TEN for the suspected drugs: (a) Allopurinol, (b) Loxoprofen, (c) Acetaminophen, (d) Carbamazepine, (e) Lamotrigine, (f) Phenytoin, (g) Furosemide, (h) ACE inhibitors, and (i) Corticosteroids

See this image and copyright information in PMC

References

1. Mockenhaupt M, Schöpf E. Epidemiology of drug-induced severe skin reactions. Semin Cutan Med Surg. 1996;15:236–43. doi: 10.1016/S1085-5629(96)80036-8. - DOI - PubMed
1. Rosen AC, Balagula Y, Raisch DW, Garg V, Nardone B, Larsen N, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25:225–34. doi: 10.1097/CAD.0000000000000032. - DOI - PMC - PubMed
1. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol. 2006;6:543–9. doi: 10.1016/j.intimp.2005.11.012. - DOI - PubMed
1. Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119:225–30. doi: 10.1046/j.1365-2249.2000.01119.x. - DOI - PMC - PubMed
1. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int. 2007;56:419–25. doi: 10.2332/allergolint.O-07-483. - DOI - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database

Affiliations

Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database

Authors

Affiliations

Abstract

Figures

References

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous